159 related articles for article (PubMed ID: 36059490)
1. Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans.
Wen L; Huang Y; Peng L; Zhao K; Sun Y; Lin Z; Chen Y; Li Z; Qian Q; Tong F; Zhang R; Dong X
Front Immunol; 2022; 13():807915. PubMed ID: 36059490
[TBL] [Abstract][Full Text] [Related]
2. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
[TBL] [Abstract][Full Text] [Related]
4. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
Front Immunol; 2021; 12():799206. PubMed ID: 34975912
[TBL] [Abstract][Full Text] [Related]
5. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells.
Haas AR; Golden RJ; Litzky LA; Engels B; Zhao L; Xu F; Taraszka JA; Ramones M; Granda B; Chang WJ; Jadlowsky J; Shea KM; Runkle A; Chew A; Dowd E; Gonzalez V; Chen F; Liu X; Fang C; Jiang S; Davis MM; Sheppard NC; Zhao Y; Fraietta JA; Lacey SF; Plesa G; Melenhorst JJ; Mansfield K; Brogdon JL; Young RM; Albelda SM; June CH; Tanyi JL
Mol Ther; 2023 Aug; 31(8):2309-2325. PubMed ID: 37312454
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
Morello A; Sadelain M; Adusumilli PS
Cancer Discov; 2016 Feb; 6(2):133-46. PubMed ID: 26503962
[TBL] [Abstract][Full Text] [Related]
7. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
Tomar S; Zhang J; Khanal M; Hong J; Venugopalan A; Jiang Q; Sengupta M; Miettinen M; Li N; Pastan I; Ho M; Hassan R
Mol Cancer Ther; 2022 Jul; 21(7):1195-1206. PubMed ID: 35499461
[TBL] [Abstract][Full Text] [Related]
8. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
O'Hara M; Stashwick C; Haas AR; Tanyi JL
Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
[TBL] [Abstract][Full Text] [Related]
10. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
Front Immunol; 2022; 13():958960. PubMed ID: 35990619
[TBL] [Abstract][Full Text] [Related]
11. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ
Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019
[TBL] [Abstract][Full Text] [Related]
12. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin-targeted CAR-T cell therapy for solid tumors.
Klampatsa A; Dimou V; Albelda SM
Expert Opin Biol Ther; 2021 Apr; 21(4):473-486. PubMed ID: 33176519
[No Abstract] [Full Text] [Related]
14. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors.
Wang Z; Li N; Feng K; Chen M; Zhang Y; Liu Y; Yang Q; Nie J; Tang N; Zhang X; Cheng C; Shen L; He J; Ye X; Cao W; Wang H; Han W
Cell Mol Immunol; 2021 Sep; 18(9):2188-2198. PubMed ID: 34381179
[TBL] [Abstract][Full Text] [Related]
15. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.
Masoumi E; Jafarzadeh L; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
J Exp Clin Cancer Res; 2020 Mar; 39(1):49. PubMed ID: 32151275
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy.
Quach HT; Skovgard MS; Villena-Vargas J; Bellis RY; Chintala NK; Amador-Molina A; Bai Y; Banerjee S; Saini J; Xiong Y; Vista WR; Byun AJ; De Biasi A; Zeltsman M; Mayor M; Morello A; Mittal V; Gomez DR; Rimner A; Jones DR; Adusumilli PS
Cancer Immunol Res; 2023 Oct; 11(10):1314-1331. PubMed ID: 37540803
[TBL] [Abstract][Full Text] [Related]
17. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
O'Hara MH; Stashwick C; Plesa G; Tanyi JL
Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
[TBL] [Abstract][Full Text] [Related]
18. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.
He J; Zhang Z; Lv S; Liu X; Cui L; Jiang D; Zhang Q; Li L; Qin W; Jin H; Qian Q
Cell Immunol; 2018 Jul; 329():31-40. PubMed ID: 29859625
[TBL] [Abstract][Full Text] [Related]
19. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth.
Yang P; Cao X; Cai H; Feng P; Chen X; Zhu Y; Yang Y; An W; Yang Y; Jie J
Cell Immunol; 2021 Feb; 360():104262. PubMed ID: 33373818
[TBL] [Abstract][Full Text] [Related]
20. Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer.
Makita Y; Kunii N; Sakurai D; Ihara F; Motohashi S; Suzuki A; Nakayama T; Okamoto Y
BMC Cancer; 2018 Dec; 18(1):1254. PubMed ID: 30558663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
